Loading…
GLYCONON, TOLBUTAMIDE is a brand name for Tolbutamide. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: As an oral hypoglycaemic agent in the treatment of diabetes mellitus of the maturity-onset type, where control cannot be achieved by diet alone. Glyconon is especially suitable for elderly patients. The hypoglycaemic effect of Tolbutamide only occurs when the beta cells of the islet tissue in the pancreas are intact…
Verbatim from this product's MHRA label. Tap a section to expand.
Adults:
Glyconon should be given with or just before meals for optimum control of blood sugar. 1st day: 6 tablets 2nd day: 3 tablets 3rd day: 2-4 tablets Maintenance: 2-3 tablets daily taken either as a single dose or divided into 2 or 3 doses.
The correct dose is that which is sufficient to correct glycosuria and hyperglycaemia without producing hypoglycaemia. The full effect of therapy may take up to a week to develop. Patients who do not respond to 4 tablets daily will generally not respond to higher doses.
Where a patient is already taking insulin, the change to Tolbutamide may be effected immediately where the dose of insulin is 20 units or less per day. Where insulin is being given in greater amounts, the number of units should be decreased over several days and glycosuria should be monitored.
Elderly:
Glyconon is particularly suitable for elderly patients. However, since this patient group may be more liable to sulphonylurea- induced hypoglycaemia, treatment should be initiated at a lower dose.
Children:
As non-insulin dependent diabetes is not usually a disease of childhood, Glyconon is not recommended for use in children.
Route of Administration:
Oral.
Gastric irritation may occur and be reduced by dividing the doses. Skin sensitisation, weakness, paraesthesias, tinnitus, headache, intolerance to alcohol and jaundice have been reported. Reversible blood dyscrasias have also been observed.
A small proportion of patients have difficulty in metabolising Tolbutamide and as a result develop hypoglycaemia even with low doses.
The possibility of thrombocytopenia and blood dyscrasias should be borne in mind and a platelet count performed if indicated. Cases which initially respond to Tolbutamide may relapse and this should be considered as a possibility should glycosuria or hyperglycaemia appear during treatment.
If fever or sore throat occurs, a white cell count should be performed and should be repeated after five days as blood abnormalities may develop slowly.
Diabetes complicated by fever, trauma or gangrene and diabetic ketoacidosis. Impaired renal, hepatic or thyroid function.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Tolbutamide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.